Increased Expression of Granzyme B and Transforming Growth Factor-β in Intralesional Plasma of Oral Lichenoid Reactions: A Preliminary Study

Kai Sun
Department of Oral Medicine, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine

Lei Pan
Department of 2nd Dental Center, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine

Yi-wen Deng
Department of Oral Medicine, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine

Jun Chen
Department of Oral Medicine, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine

Guan-huan Du
Department of Oral Medicine, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine

Chencheng Song
Department of Oral Medicine, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine

Junjun Chen
Department of Oral Medicine, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine

Xiaozhe Han
The Forsyth Institute, Department of Immunology and Infectious Diseases, Cambridge, MA

Yufeng Wang
Department of Oral Medicine, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine

Guoyao Tang (tanggy@shsmu.edu.cn)
Department of Oral Medicine, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
Abstract

**Background:** Oral lichenoid reactions are intractable inflammatory diseases of oral mucosa. The cytokine profiles of intralesional blood remain unclear. We aim at revealing the intralesional cytokine profiles and providing some actual and stable intralesional cytokine biomarkers to evaluate the severity and therapeutic effects of oral lichenoid reactions.

**Methods:** Paired intralesional and peripheral plasma from 26 patients with oral lichenoid reactions were collected. The concentration of 15 cytokines of granzyme B, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL17A, TNF-α, IFN-α, IFN-β, IFN-γ, TGF-β1, TGF-β2 and TGF-β3 was measured by Luminex assays. REU score was used for evaluating the severity of the disease.

**Results:** Eleven cytokines including IL-10, IFN-α, IL-6, IL-17A, granzyme B, TGF-β1, TGF-β2, TGF-β3, IL-2, TNF-α, IL-12p70 were detected within the reliable working range. IL-10 was detected in less intralesional samples (19/26) than peripheral samples (26/26, p=0.01). The cytokine concentrations from intralesional plasma were significantly elevated in granzyme B (median 108.94 vs. 16.00), TGF-β1 (mean 30448.92 vs. 10199.04), TGF-β2 (mean 1659.73 vs. 1308.49) and TGF-β3 (mean 914.33 vs. 573.13) than that in peripheral plasma (p=0.001, p<0.001, p<0.001 and p<0.001, respectively). The concentration of IL-12p70 in peripheral plasma was positively correlated with REU score (coefficient of correlation=0.463, p=0.02).

**Conclusions:** The concentration of granzyme B and TGF-β are more abundant in intralesional microenvironment than in peripheral plasma of oral lichenoid reactions. IL-12p70 may be a potential molecular biomarker for evaluating the severity of oral lichenoid reactions. Cohort study of large population is required.

Introduction

Oral lichenoid reactions (OLRs) are considered to represent a spectrum of diseases which involve the interface of oral mucosa. OLRs can be classified as oral lichen planus (OLP) and its sister disease, oral lichenoid lesion (OLL), which include oral lichenoid contact reactions, oral lichenoid drug eruptions and oral lichenoid reactions of graft-versus-host disease etc. [1]. The global prevalence of OLP is 0.89% among the general population [2]. The exact etiology of OLRs is not fully elucidated [3]. A common feature of these diseases is that T cells are activated in the microenvironment of lesions [4].

Cytokines are proteins with pleiotropism and redundancy. Among the numerous cytokines, T cell-associated cytokine profiles have been widely investigated with peripheral blood or saliva samples in the field of OLRs. However, different samples may express altered levels of cytokine. For instance, tumor necrosis factor-α (TNF-α), which is extensively studied in OLRs, was increased in lesions and saliva of OLP compared to health controls [5, 6], while in peripheral blood mononuclear cells (PBMCs) from OLP patients, the concentration of TNF-α was decreased [7]. In our previous study, a complicated Th1/Th2-related cytokine profile was found from the saliva of OLL patients [8], indicating a complex regulatory network in the pathogenesis of OLRs.
Cytokines exert a transient immunomodulatory function at high local concentrations in autocrine or paracrine fashions [9-11]. They are also elevated in peripheral blood in endocrine fashion in some inflammatory diseases [12]. However, in most oral mucosal diseases, cytokines do not work in endocrine fashion [13]. Therefore, it seems inaccurate to monitor the severity of OLRs through the cytokines from peripheral blood. Meanwhile, the level of salivary cytokines is greatly affected by factors such as oral microorganism, collection time and method, making it unstable for reflecting the severity of OLRs.

Recently, it was reported that the cytokines from intralesional blood contain disease-specific biomarkers and have diagnostic and prognostic functions [14]. In this study, we will collect intralesional blood samples to detect the OLRs-related cytokine profiles, aiming at revealing some actual and stable cytokine biomarkers to monitor the development of OLRs.

**Methods**

**Study design**

This study was independently reviewed and approved by the Ethics Committee of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine (approval ID: SH9H-2020-TK376-1, approved on May 25th, 2020) and conducted according to the Declaration of Helsinki and the additional requirements. This study was undertaken with the understanding and written informed consent of each participant. We conducted this preliminary study in patients with OLRs from department of oral medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. We included patients whose diagnoses were OLRs according to the modified WHO criteria [15]. Patients who used topical or systemic corticosteroids within 3 months were excluded. We also excluded patients with graft-versus-host disease. Intralesional and peripheral blood samples from 26 patients were collected for study.

**Collection of intralesional and peripheral blood**

Fluconazole 50 mg daily as well as 1% sodium bicarbonate solution was used for approximately 2 weeks prior to blood collection. After local anesthesia, 5 mm incision was made in the lesion at a depth of approximately 3 mm. The intralesional blood was collected at the site of lesion (buccal mucosa or tongue), and collected immediately into an EDTA-embedded Eppendorf tube, followed by centrifugation at 6000 rpm for 8 minutes. The supernatant plasma was then collected and stored at -80 °C.

**Cytokine concentration analysis**

According to our previous study [8], the cytokine profile is this study consisted of totally 15 selected cytokines, which could be divided into four subgroups. The first subgroup included T helper (Th)1 cytokines: IL-2, TNF-α, IFN-α, IFN-β, IFN-γ and IL-12p70. The second subgroup included Th2 cytokines: IL-4, IL-5, IL-6 and IL-10. The third subgroup included Th17 cytokines: IL17A. The other cytokines, which
included transforming growth factor (TGF)-β1, TGF-β2, TGF-β3 and granzyme B, were divided as the fourth subgroup.

The cytokine profile was detected and measured with Human XL Cytokine Luminex Performance Panel Premixed Kit (R&D Systems, Minneapolis, USA, Cat. No FCSTM18) and Bio-Plex Pro™ TGF-β 3-plex Assay (Bio-Rad, California, USA, Cat. No 171W4001M) according to the manufacturers’ protocols. Briefly, 50 µL of diluted resuspended beads were embedded into each well in a 96-well plate to capture antibodies. Then, 50 µL of standard substance and samples were added. Diluted biotin labeled antibody complex, streptavidin labeled PE and detergent were added accordingly into each well, and fluorescence intensity readings for the standards and samples were detected on a Luminex 200 sorting and detection platform (Luminex Inc., Texas, USA). Fluorescence data were furtherly converted into the corresponding cytokine concentrations through the R&D Analyst software.

From the standard curve, the reliable working range of each cytokine could be illustrated and the detection rate could be calculated. When the detection rate of a given cytokine in any of the intralesional or peripheral plasma group was over 60%, the detection rates could be compared. When the detection rate of a given cytokine in both intralesional and peripheral plasma groups were over 80%, the concentrations could be numerically compared [16]. Each sample was detected once due to the limited quantity of the samples.

Evaluation of severity

The REU score system was used to evaluate the severity of OLRs according to previously publication [17]. In brief, oral cavity was divided into totally 10 sites: labial mucosa, right buccal mucosa, left buccal mucosa, dorsal tongue, ventral tongue, floor of mouth, hard palate mucosa, soft palate/tonsillar pillars, maxillary gingiva, mandibular gingiva. In this system, R represents reticular/hyperkeratotic lesions and each site scored from 0 to 1; E and U represent erosive/erythematous and ulcerative areas, respectively, and both scored in each site from 0 to 3. REU score was calculated through the formula that REU score=1×ΣR+1.5×ΣE+2×ΣU.

Statistical Analysis

The results of continuous variables were presented in the form of means ± standard deviations (SD) or median (interquartile range, IQR). Independent t-test and Mann-Whitney U test were performed where data were of normal distribution and non-normal distribution, respectively. Chi-square or Fisher exact probability test was used for calculating the differences of detection rates. Spearman’s correlation test was used to analyze the correlations between REU scores and cytokine concentrations, and results were presented as coefficient of correlation (R). The REU score was not applicable in 1 subject where series mean of replacing missing values was used. Data analysis was performed using SPSS 24.0 software (Armonk, New York, USA). Graph Prism 7 (Graph Pad Software, CA, USA) was used for graphic figures. Possibility (p) value less than 0.05 was considered statistically significant.
Results

Participant characteristics

In total, 26 participants with OLRs were enrolled in our study, in which 14 (53.85%) were diagnosed as OLP and 12 (46.15%) were OLL. The number of female participants was larger than that of male participants (17 females and 9 males). The average age was 49.27±13.77 years. Detailed information on lesion site, systemic diseases, drugs used within 3 months and REU score of each participant was described in Table 1.

Detection rate of cytokines

The cytokines whose detection rates in both intralesional and peripheral plasma were more than 80% included granzyme B, IL-2, IL-12p70, TNF-α, TGF-β1, TGF-β2 and TGF-β3. Concentrations of these 7 cytokines would be further analyzed. For IFN-α, IL-6, IL-10 and IL-17A, the detection rates were compared (Table 2). For IFN-β, IFN-γ, IL-4 and IL-5, the detection rate in either group was less than 60%, which could not be analyzed qualitatively or quantitatively.

IL-10 was detected within the reliable working range in 19 intralesional samples (19/26, 73.08%) and all the 26 peripheral samples (26/26, 100%, p=0.010). IFN-α was detected in 23 intralesional sample (23/26, 88.46%) compared to 20 peripheral samples (20/26, 76.92%, p=0.465). IL-6 was detected in 19 intralesional samples (19/26, 73.08%) compared to 21 peripheral samples (21/26, 80.77%, p=0.510). The detection rate of IL-17A was slightly lower in intralesional samples (16/26, 61.54%) compared to that in peripheral samples (19/26, 73.08%, p=0.375). These data indicated that IL-10 was expressed in more peripheral plasma samples than intralesional plasma (Figure 1).

Comparisons of cytokine concentrations

In the participants with OLRs, the cytokine concentrations in intralesional plasma are significantly elevated in granzyme B, TGF-β1, TGF-β2 and TGF-β3 than that in peripheral plasma (p=0.001, p<0.001, p<0.001 and p<0.001, respectively, Table 3, Figure 2A-D). The cytokine concentrations of IL-2 and TNF-α in intralesional plasma are significantly lower than those in peripheral plasma (p=0.009 and p=0.048, respectively, Table 3, Figure 2E-F). For IL-12p70 and, no significant difference was found (p=0.697, Figure 2G).

Correlation of REU score and cytokine concentrations

In the participants with OLL, the concentration of IL-12p70 in peripheral plasma was positively correlated with REU score (coefficient of correlation=0.463, p=0.02, Table 4). No significant correlation between REU score and cytokine concentration was found in intralesional plasma of IL-12p70 or other detected cytokines.

Discussion
In this study, participants with OLRs were enrolled instead of OLP alone. Up to now, the diagnostic criteria to distinguish OLP from OLL are still lacking [18]. OLL has frequently been used to refer to indicate an uncertain diagnosis of OLP [19]. As a typical spectrum of interface oral mucositis, OLRs could, to a large extent, reflect the features of microenvironment of OLP.

There are few studies on the regional immune characteristics of oral mucosa in recent years. OLRs are intractable inflammatory diseases mainly caused by immune deficiency or dysregulation of oral immune system [20]. Cytokines are reliable biomarker for monitor the severity of inflammatory diseases [21, 22]. In this study, unlike many previous studies on cytokine profiles from PBMCs between diseased and healthy subjects, we detected cytokine concentrations of intralesional and peripheral plasma from the participants, aiming at providing a more regional immune profiles of OLRs and revealing a reliable biomarker for monitoring the severity of OLRs on the molecular level.

We find the concentration of granzyme B as well as TGF-β is higher in intralesional plasma of OLRs than those in peripheral plasma. It is reported that increased expression of granzyme B in OLP lesions are found compared to cutaneous lichen planus, which is consistent with our findings [23]. The concentration of TGF-β in OLRs is controversial. In our previous study, salivary TGF-β is not significantly different between OLP and healthy control [8], while Zenouz et al. reveals a significant decrease in the serum levels of TGF-β from OLP patients [24]. These findings suggest that lesional granzyme B can be a potential biomarker for diagnosis of OLRs, and further studies are warranted for evaluating whether lesional granzyme B or TGF-β can be used to monitor the disease activity and therapeutic effects of OLRs.

Like granzyme B, TNF-α is another important cytokine that involves in killing target cells. In our study, concentration of TNF-α is decreased in intralesional plasma of OLL, which may due to the compensatory effect of granzyme B. Besides, It is reported that different detecting methods may lead to different results. Most studies observed elevated levels of TNF-α in the serum of patients with OLL through ELISA [25, 26], while when bead-based flow cytometry was used, no statistical difference was found in the serum levels of TNF-α between patients with OLP and health control [8, 27]. Further comparisons among various methods for cytokine detection are required.

In this study, the concentration of IL-12p70 in peripheral plasma is positively correlated with REU score, and the concentration of IL-12p70 in intralesional plasma is not statistically different from that in peripheral plasma. Considering that intralesional plasma is always collected with invasive examination of oral mucosa, and that executing invasive oral examination regularly is unrealistic, IL-12p70 in peripheral plasma may be appropriate for monitoring OLRs. Higher levels of IL-12 are found in systemic lupus erythematosus patients compared to controls, and p40 subunit serum levels were found to be positively correlated with the severity of the disease, which is in consistent with our result. Ohno et al. reported that PBMCs from OLP patients produced higher amounts of IL-12 than those from healthy controls [28]. Janardhanam et al. reported the salivary epithelial cells from OLP subjects express increased IL-12 than from health control [29]. These findings suggest IL-12 as a potential diagnostic
biomarker for OLP. However, the function of salivary IL-12 in monitoring the severity of the disease needs to be proved by further study.

There exist some limitations in this preliminary study. The concentration of some cytokine is below the lower limitation. Neither detection rate of IFN-γ or IL-4, which represent Th1/Th2 cytokines, meets the criteria for data analysis. As the Th1/Th2 imbalance is controversial [30, 31], further studied using methods with more sensitivity are needed in future. Besides, in the process of intralesional blood collection, the volume of the collected blood from few patients cannot meet the need for Luminex assay. A standard collection protocol of intralesional blood is essential for future study. In addition, due to ethic problems, we do not collect the intralesional plasma from healthy control subjects as well as from participants after treatment, which restricted us from comparing our data with these control groups.

**Conclusions**

In this preliminary study, the concentration of granzyme B and TGF-β are more abundant in intralesional microenvironment of OLRs than in peripheral plasma. IL-12p70 may be a potential molecular biomarker for evaluating the severity of OLRs. Cohort study of large population should be considered to furtherly confirm our results.

**List Of Abbreviations**

- IFN, interferon
- IL, interleukin.
- IQR, interquartile range.
- OLL, oral lichenoid lesion.
- OLP, oral lichen planus.
- OLRs, oral lichenoid reactions.
- PBMCs, peripheral blood mononuclear cells.
- SD, standard deviations.
- TGF, transforming growth factor.
- TNF, tumor necrosis factor.

**Declarations**

**Ethics approval and consent to participate**
This study was independently reviewed and approved by the Ethics Committee of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine (approval ID: SH9H-2020-TK376-1, approved on May 25th, 2020) and conducted according to the Declaration of Helsinki and the additional requirements. This study was undertaken with the understanding and written informed consent of each participant.

**Consent for publication**

Not applicable

**Available of data and materials**

The datasets used during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study was supported by National Natural Science Foundation of China, Grant No.81730030 and No.81970937, Seed Funding of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Grant No.JYZZ046 and No.JYZZ106.

**Authors’ contributions**

KS, Methodology, Data Curation, Validation, Writing Original Draft, Formal Analysis, Funding, Resources. LP, Methodology, Data Curation, Writing Review & Editing. YWD, Methodology, Resources. JC, Methodology, Resources. GHD, Resources. CS, Methodology. JC, Methodology, Resources. XH, Investigation. YW, Conceptualization, Resources, Funding. GT, Conceptualization, Visualization, Funding. All authors read and approved the final manuscript.

**Acknowledgements**

We thank for Prof. Fu-xiang Chen, Dr. Gui-fang Gan of the laboratory department of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine for providing the administrative support and samples of peripheral blood for this study. The authors declare no conflict of interest.

**Author details**

1 Department of Oral Medicine, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine; National Clinical Research Center for Oral Disease; Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China
References

1. Glick M. Burket's oral medicine 12th ed,2015 (in Persian - Vol 2). People's Medical Publishing House, USA. 2018. p. 104.

2. Li C, Tang X, Zheng X, Ge S, Wen H, Lin X, Chen Z, Lu L: Global Prevalence and Incidence Estimates of Oral Lichen Planus: A Systematic Review and Meta-analysis. JAMA dermatology. 2020.

3. Hasan S, Ahmed S, Kiran R, Panigrahi R, Thachil JM, Saeed S: Oral lichen planus and associated comorbidities: An approach to holistic health. J Family Med Prim Care. 2019; 8(11):3504-17.

4. Thongprasom K: Oral lichen planus: Challenge and management. Oral diseases. 2018; 24(1-2):172-3.

5. Rhodus NL, Cheng B, Bowles W, Myers S, Miller L, Ondrey F: Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone. Oral diseases. 2006; 12(2):112-6.

6. Younes F, Quartey EL, Kiguwa S, Partridge M: Expression of TNF and the 55-kDa TNF receptor in epidermis, oral mucosa, lichen planus and squamous cell carcinoma. Oral diseases. 1996; 2(1):25-31.

7. Simark-Mattsson C, Eklund C: Reduced immune responses to purified protein derivative and Candida albicans in oral lichen planus. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2013; 42(9):691-7.

8. Wei W, Sun Q, Deng Y, Wang Y, Du G, Song C, Li C, Zhu M, Chen G, Tang G: Mixed and inhomogeneous expression profile of Th1/Th2 related cytokines detected by cytometric bead array in the saliva of patients with oral lichen planus. Oral surgery, oral medicine, oral pathology and oral radiology. 2018; 126(2):142-51.

9. Hedl M, Sun R, Abraham C: Disease Risk-Associated Genetic Variants in STAT1 and STAT4 Function in a Complementary Manner to Increase Pattern-Recognition Receptor-Induced Outcomes in Human Macrophages. Journal of immunology. 2020.

10. Rodgers KR, Lin Y, Langan TJ, Iwakura Y, Chou RC: Innate Immune Functions of Astrocytes are Dependent Upon Tumor Necrosis Factor-Alpha. Sci Rep. 2020; 10(1):7047.

11. Wenzel TJ, Kwong E, Bajwa E, Klegeris A: Resolution-Associated Molecular Patterns (RAMPs) as Endogenous Regulators of Glia Functions in Neuroinflammatory Disease. CNS Neurol Disord Drug Targets. 2020.
12. Kim YK, Na KS, Myint AM, Leonard BE: The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016; 64:277-84.

13. Lu R, Zhang J, Sun W, Du G, Zhou G: Inflammation-related cytokines in oral lichen planus: an overview. Journal of oral pathology & medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2015; 44(1):1-14.

14. Ishimoto T, Kataoka S, Shiga T, Takaishi M, Sano S: Use of intralesional blood to determine diffusible biomarkers from skin lesions. Journal of dermatological science. 2018; 90(1):75-81.

15. van der Meij EH, van der Waal I: Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. Journal of oral pathology & medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2003; 32(9):507-12.

16. Lu B, Yin H, Tang Q, Wang W, Luo C, Chen X, Zhang X, Lai K, Xu J, Chen X et al: Multiple cytokine analyses of aqueous humor from the patients with retinitis pigmentosa. Cytokine. 2020; 127:154943.

17. Piboonniyom SO, Treister N, Pitiphat W, Woo SB: Scoring system for monitoring oral lichenoid lesions: a preliminary study. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2005; 99(6):696-703.

18. Feldmeyer L, Suter VG, Oeschger C, Cazzaniga S, Bornstein MM, Simon D, Borradori L, Beltraminelli H: Oral lichen planus and oral lichenoid lesions - an analysis of clinical and histopathological features. Journal of the European Academy of Dermatology and Venereology: JEADV. 2020; 34(2):e104-7.

19. Carrozzo M, Porter S, Mercadante V, Fedele S: Oral lichen planus: A disease or a spectrum of tissue reactions? Types, causes, diagnostic algorithms, prognosis, management strategies. Periodontol 2000. 2019; 80(1):105-25.

20. Wu RQ, Zhang DF, Tu E, Chen QM, Chen W: The mucosal immune system in the oral cavity - an orchestra of T cell diversity. International journal of oral science. 2014; 6(3):125-32.

21. Beringer A, Miossec P: Systemic effects of IL-17 in inflammatory arthritis. Nature reviews Rheumatology. 2019; 15(8):491-501.

22. Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Yssel H, Garrido Castillo L, Cohen-Aubart F, Haroche J, Hié M, Pineton de Chambrun M, et al: Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse. Annals of the rheumatic diseases. 2019; 78(12):1669-76.

23. Lage D, Pimentel V, Soares T, Souza E, Metze K, Cintra M: Perforin and granzyme B expression in oral and cutaneous lichen planus - a comparative study. Journal of cutaneous pathology. 2011; 38(12):973-8.

24. Taghavi Zenouz A, Pouralibaba F, Babaloo Z, Mehdipour M, Jamali Z: Evaluation of Serum TNF-α and TGF-β in Patients with Oral Lichen Planus. Journal of dental research, dental clinics, dental prospects. 2012; 6(4):143-7.
25. Sun A, Chia J, Wang J, Chiang C: Levamisole can reduce the high serum tumour necrosis factor-alpha level to a normal level in patients with erosive oral lichen planus. Clinical and experimental dermatology. 2007; 32(3):308-10.

26. Zhou Z, Wei B, Shi P: Osteopontin expression in oral lichen planus. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2008; 37(2):94-8.

27. Pekiner F, Demirel G, Borahan M, Ozbayrak S: Cytokine profiles in serum of patients with oral lichen planus. Cytokine. 2012; 60(3):701-6.

28. Ohno S, Tateishi Y, Tatemoto Y, Morishita K, Sasabe E, Yamamoto T: Enhanced expression of Toll-like receptor 2 in lesional tissues and peripheral blood monocytes of patients with oral lichen planus. The Journal of dermatology. 2011; 38(4):335-44.

29. Janardhanam S, Prakasam S, Swaminathan V, Kodumudi K, Zunt S, Srinivasan M: Differential expression of TLR-2 and TLR-4 in the epithelial cells in oral lichen planus. Archives of oral biology. 2012; 57(5):495-502.

30. Wang F, Zhang J, Zhou G: The mTOR-glycolytic pathway promotes T-cell immunobiology in oral lichen planus. Immunobiology. 2020; 225(3):151933.

31. Wang H, Zhang D, Han Q, Zhao X, Zeng X, Xu Y, Sun Z, Chen Q: Role of distinct CD4(+) T helper subset in pathogenesis of oral lichen planus. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2016; 45(6):385-93.

**Tables**

**Table 1. Description of clinical characteristics of the participants with OLRs.**
| No. | Gender | Age (years) | Lesion Site          | Systemic Disease                               | Drugs Used within 3 Months                              | REU score | Diagnosis |
|-----|--------|-------------|----------------------|------------------------------------------------|--------------------------------------------------------|-----------|-----------|
| 1   | F      | 69          | dorsum of tongue     | osteoporosis, rheumatoid arthritis             | vitamin D3, calcium, glucosamine hydrochloride          | 8         | OLP       |
| 2   | F      | 56          | buccal mucosa        | hypertension, hyperlipidemia                   | telmisartan, amlodipine aspartate, fenofibrate          | 5         | OLL       |
| 3   | F      | 45          | buccal mucosa        | denied                                         | denied                                                 | 5         | OLP       |
| 4   | M      | 34          | buccal mucosa        | denied                                         | denied                                                 | 2         | OLP       |
| 5   | F      | 58          | buccal mucosa        | hypertension                                    | amlodipine, vitamins                                   | 2         | OLL       |
| 6   | F      | 62          | buccal mucosa        | hypertension, oral leukoplakia                  | valsartan, concentrated tinidazole gargles              | 3         | OLP       |
| 7   | M      | 39          | buccal mucosa        | denied                                         | denied                                                 | 4         | OLL       |
| 8   | F      | 49          | buccal mucosa        | denied                                         | cefdinir                                              | 3         | OLP       |
| 9   | M      | 32          | dorsum of tongue     | denied                                         | denied                                                 | 7.5       | OLL       |
| 10  | F      | 61          | buccal mucosa        | carotid plaque, chronic gastritis, facial paralysis | rosuvastatin calcium, omeprazole, artificial bezoar metronidazole, mecobalamin | 15        | OLP       |
| 11  | F      | 64          | buccal mucosa        | denied                                         | denied                                                 | 11.5      | OLL       |
| 12  | F      | 39          | buccal mucosa        | malignant teratoma                              | denied                                                 | 6.5       | OLP       |
| 13  | M      | 65          | buccal mucosa        | diabetes mellitus, hypertension, cerebral insufficiency of blood supply | metformin hydrochloride, irbesartan and hydrochlorothiazide, TCM for promoting blood circulation (Yin Dan Xin Nao Tong capsule) | 13        | OLL       |
| 14  | F      | 67          | buccal mucosa        | denied                                         | denied                                                 | 5.5       | OLP       |
|   |   |   |                |          |          |   |   |
|---|---|---|----------------|----------|----------|---|---|
| 15| M | 30| buccal mucosa  | denied   | denied   | 8 | OLP|
| 16| F | 25| buccal mucosa  | NA       | NA       | NA| OLP|
| 17| F | 44| buccal mucosa  | denied   | denied   | 3 | OLP|
| 18| M | 25| ventral tongue | denied   | denied   | 7 | OLP|
| 19| M | 58| buccal mucosa  | diabetes mellitus, lacunar infarction, hypertension | metformin hydrochloride, atorvastatin calcium, valsartan | 10 | OLL|
| 20| M | 46| buccal mucosa  | denied   | denied   | 4.5 | OLL|
| 21| F | 56| buccal mucosa  | diabetes mellitus, psoriasis | metformin hydrochloride | 10 | OLP|
| 22| F | 55| buccal mucosa  | lumbar disc protrusion | mecobalamin | 10 | OLP|
| 23| M | 55| ventral tongue | denied   | TCM for clearing heat and toxic material (Bi Bai Ke caspule) | 4.5 | OLL|
| 24| F | 48| buccal mucosa  | chronic gastritis | vitamin U, belladonna and aluminium capsules, cefdinir | 6 | OLP|
| 25| F | 32| buccal mucosa  | denied   | denied   | 4 | OLP|
| 26| F | 67| buccal mucosa  | denied   | vitamins  | 7 | OLL|

OLRs, oral lichenoid reactions; OLL, oral lichenoid lesion; F, female; M, male; TCM, traditional Chinese medicine; NA, not applicable.

Table 2. Detection rate of each cytokine
| Cytokines    | Range (pg/ml) | No. of samples | P     |
|-------------|---------------|----------------|-------|
|             | Intralesional | Peripheral     |       |
| Granzyme B* | 3.46-29884    | 25/26          | 24/26 | 1.000 |
| IFN-α*      | 1.54-38240    | 23/26          | 20/26 | 0.465 |
| IFN-β*      | 1.27-29364    | 1/26           | 5/26  | 0.191 |
| IFN-γ       | 2.94-42396    | 0/26           | 12/26 | <0.001|
| IL-2*       | 1.22-31590    | 26/26          | 26/26 | -     |
| IL-4        | 0.41-9564     | 4/26           | 14/26 | 0.004 |
| IL-5*       | 2.49-47546    | 0/26           | 4/26  | 0.110 |
| IL-6        | 3.84-71032    | 19/26          | 21/26 | 0.510 |
| IL-10*      | 18.42-203564  | 19/26          | 26/26 | 0.010 |
| IL-12p70*   | 7.57-155916   | 23/26          | 25/26 | 0.610 |
| IL-17A      | 2.84-80204    | 16/26          | 19/26 | 0.375 |
| TNF-α*      | 4.53-106272   | 23/26          | 23/26 | 1.000 |
| TGF-β1      | 5.50-334970   | 26/26          | 26/26 | -     |
| TGF-β2      | 12.40-388090  | 26/26          | 26/26 | -     |
| TGF-β3*     | 4.05-370010   | 25/26          | 26/26 | 1.000 |

Chi-square was used. *, Fisher exact possibility test was used. The concentrations of granzyme B, IL-2, IL-12p70, TNF-α, TGF-β1, TGF-β2 and TGF-β3 could be further analyzed due to the high detection rate. IFN, interferon; IL, interleukin; TNF, tumor necrosis factor; TGF, transforming growth factor.

**Table 3. Comparisons of cytokine concentrations of intralesional and peripheral plasma of OLRs samples.**
Cytokines & Concentrations (pg/ml) & P 
\hline
 & Intralesional & Peripheral & 
\hline
Granzyme B & 108.94 (57.80,404.94) & 26.00 (20.25,58.98) & <0.001 
IL-2 & 2.84 (2.04,3.26) & 3.45 (2.49-5.53) & 0.019 
IL-12p70 & 10.59 (8.41,12.93) & 10.59 (8.41,11.76) & 0.697 
TNF-α & 7.66 (6.82,9.42) & 10.34 (7.66,12.24) & 0.048 
TGF-β1 & 30448.92±19210.18 & 10199.04±5303.33 & <0.001 
TGF-β2 & 1659.73±319.49 & 1308.49±166.85 & <0.001 
TGF-β3 & 914.33±232.90 & 573.13±208.32 & <0.001 
\hline

Data are presented as mean ± standard deviations or median (25% interquartile, 75% interquartile) where appropriate. OLRs, oral lichenoid reactions; IL, interleukin; TNF, tumor necrosis factor; TGF, transforming growth factor.

**Table 4. Correlations between REU score and cytokines.**

| Cytokines | Intralesional | Peripheral |
|-----------|---------------|------------|
|           | R  | p  | R  | p  |
| Granzyme B | 0.017 | 0.936 | -0.102 | 0.634 |
| IFN-α     | 0.012 | 0.955 | 0.165 | 0.499 |
| IL-2      | 0.072 | 0.725 | 0.093 | 0.652 |
| IL-4      | 0.943 | 0.057 | -0.08 | 0.785 |
| IL-6      | -0.116 | 0.637 | 0.015 | 0.947 |
| IL-10     | -0.105 | 0.669 | 0.028 | 0.891 |
| IL-12p70  | 0.339 | 0.113 | 0.463 | 0.02* |
| IL-17A    | 0.041 | 0.879 | 0.031 | 0.899 |
| TNF-α     | -0.035 | 0.876 | 0.046 | 0.836 |
| TGF-β1    | -0.254 | 0.21 | 0.077 | 0.707 |
| TGF-β2    | -0.117 | 0.57 | 0.357 | 0.073 |
| TGF-β3    | -0.254 | 0.22 | 0.175 | 0.392 |

R, coefficient of correlation. *, p<0.05. IL, interleukin; TNF, tumor necrosis factor; TGF, transforming growth factor.